- Conditions: Chronic Kidney Failure; End-stage Renal Disease; Disorders Associated With Peritoneal Dialysis
Intervention: Drug: lanthanum carbonate
Sponsors: Los Angeles Biomedical Research Institute; Los Angeles Biomedical Research Institute
Recruiting - verified April 2012 - Condition: Attention-deficit/Hyperactivity Disorder
Interventions: Drug: Lisdexamfetamine dimesylate; Drug: Methylphenidate Hydrochloride; Drug: Placebo
Sponsors: Shire Development LLC; Shire Development LLC
Recruiting - verified May 2012 - Condition: Attention-deficit/Hyperactivity Disorder
Interventions: Drug: Lisdexamfetamine dimesylate; Drug: Methylphenidate Hydrochloride; Drug: Placebo
Sponsors: Shire Development LLC; Shire Development LLC
Recruiting - verified May 2012 - Condition: Healthy
Interventions: Drug: Anagrelide 0.5 mg; Drug: Anagrelide 2.5 mg; Drug: Moxifloxacin; Drug: Placebo
Sponsors: Shire Development LLC; Shire Development LLC
Recruiting - verified April 2012 - Conditions: Tourette Disorder; Tourette Syndrome
Interventions: Drug: placebo; Drug: extended-release guanfacine (Intuniv)
Sponsors: Yale University; Yale University; New York University; University of South Florida; Shire Development LLC
Recruiting - verified May 2012 - Condition: Orthostatic Hypotension
Interventions: Drug: Midodrine HCl; Drug: Placebo
Sponsors: Shire Development LLC; Shire Development LLC
Not yet recruiting - verified January 2012 - Condition: Symptomatic Orthostatic Hypotension
Interventions: Drug: Midodrine HCl; Drug: Placebo
Sponsors: Shire Development LLC; Shire Development LLC
Not yet recruiting - verified January 2012 - Condition: Sanfilippo Syndrome Type B
Intervention:
Sponsors: Shire Human Genetic Therapies, Inc.; Shire Human Genetic Therapies, Inc.
Recruiting - verified March 2012 - Condition: ADHD
Intervention: Drug: Extended-release Guanfacine HCl (Intuniv, SPD503)
Sponsors: Shire Development LLC; Shire Development LLC
Enrolling by invitation - verified March 2012 - Condition: Leukodystrophy, Metachromatic
Intervention: Biological: Recombinant human arylsulfatase A
Sponsors: Shire Human Genetic Therapies, Inc.; Shire Human Genetic Therapies, Inc.
Active, not recruiting - verified April 2012 - Condition: Hunter Syndrome
Intervention: Drug: Idursulfase-IT
Sponsors: Shire Human Genetic Therapies, Inc.; Shire Human Genetic Therapies, Inc.
Recruiting - verified January 2012 - Condition: Gastroesophageal Reflux Disease
Interventions: Drug: SSP-002358 (0.1 mg) + PPI; Drug: SSP-002358 (0.5 mg) + PPI; Drug: SSP-002358 (2.0 mg) + PPI; Drug: Placebo + PPI
Sponsors: Shire-Movetis NV; Shire-Movetis NV
Recruiting - verified May 2012 - Conditions: Generalized Anxiety Disorder (GAD); Anxiety, Separation; Phobia, Social
Interventions: Drug: SPD503 (extended-release Guanfacine hydrochloride); Drug: Placebo
Sponsors: Shire Development LLC; Shire Development LLC
Recruiting - verified April 2012 - Condition: Healthy
Interventions: Drug: sulfamethoxazole + MMX placebo; Drug: Sulfamethoxazole + MMX Mesalazine/mesalamine
Sponsors: Shire Development LLC; Shire Development LLC
Completed - verified January 2012 - Condition: Essential Thrombocythaemia
Intervention: Drug: SPD422 (anagrelide hydrochloride)
Sponsors: Shire Development LLC; Shire Development LLC
Recruiting - verified March 2012 - Condition: Schizophrenia
Interventions: Drug: SPD489 (Lisdexamfetamine dimesylate); Drug: Placebo
Sponsors: Shire Development LLC; Shire Development LLC
Completed - verified February 2012 - Condition: Hunter Syndrome
Intervention: Other: No treatment will be administered in this study
Sponsors: Shire Human Genetic Therapies, Inc.; Shire Human Genetic Therapies, Inc.
Recruiting - verified February 2012 - Condition: Hereditary Angioedema
Intervention: Drug: Icatibant
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; Shire Human Genetic Therapies, Inc.
Recruiting - verified April 2012 - Condition: Healthy
Interventions: Drug: Amoxicillin + MMX placebo; Drug: Amoxicillin + MMX mesalazine/mesalamine
Sponsors: Shire Development LLC; Shire Development LLC
Completed - verified November 2011 - Condition: Major Depressive Disorder
Interventions: Drug: Antidepressant + SPD489 (Lisdexamfetamine dimesylate ); Drug: Antidepressant + Placebo
Sponsors: Shire Development LLC; Shire Development LLC
Recruiting - verified March 2012 - Condition: Major Depressive Disorder
Interventions: Drug: SPD489 (Lisdexamfetamine dimesylate ); Drug: Placebo
Sponsors: Shire Development LLC; Shire Development LLC
Recruiting - verified May 2012 - Condition: Major Depressive Disorder
Interventions: Drug: Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 10 mg; Drug: Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 30 mg; Drug: Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 50 mg; Drug: Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 70 mg; Drug: Antidepressant + Placebo
Sponsors: Shire Development LLC; Shire Development LLC
Recruiting - verified March 2012 - Condition: Major Depressive Disorder
Intervention: Drug: SPD489 (Lisdexamfetamine dimesylate) + Antidepressant
Sponsors: Shire Development LLC; Shire Development LLC
Enrolling by invitation - verified May 2012 - Condition: Healthy
Interventions: Drug: Metronidazole + MMX Mesalazine/mesalamine placebo; Drug: Metronidazole + MMX Mesalazine/mesalamine
Sponsors: Shire Development LLC; Shire Development LLC
Completed - verified October 2011 - Condition: Healthy
Interventions: Drug: SSP-002358; Drug: SSP-002358 + omeprazole
Sponsors: Shire-Movetis NV; Shire-Movetis NV
Completed - verified February 2012 - Condition: Attention Deficit Disorder With Hyperactivity
Intervention: Drug: Lisdexamfetamine dimesylate
Sponsors: Maastricht University Medical Center; Maastricht University Medical Center; Shire Development LLC
Not yet recruiting - verified August 2011 - Condition: Healthy
Interventions: Drug: Ciprofloxacin XR + MMX Placebo; Drug: MMX Mesalazine/mesalamine + Ciprofloxacin XR
Sponsors: Shire Development LLC; Shire Development LLC
Completed - verified November 2011 - Condition: Attention Deficit Hyperactivity Disorder
Interventions: Drug: Lisdexamfetamine; Drug: Placebo
Sponsors: Columbia University; Columbia University; Shire Development LLC
Not yet recruiting - verified August 2011 - Condition: Hereditary Angioedema
Intervention: Drug: icatibant
Sponsors: Shire Human Genetic Therapies, Inc.; Shire Human Genetic Therapies, Inc.
Recruiting - verified May 2012 - Conditions: Post Infective IBS-D; Irritable Bowel Syndrome With Diarrhea
Intervention: Drug: Mesalamine
Sponsors: University of Utah; University of Utah; Shire Human Genetic Therapies, Inc.
Recruiting - verified August 2011 - Condition: Gastroesophageal Reflux Disease
Interventions: Drug: M0003 (SPD557); Drug: placebo
Sponsors: Movetis; Movetis
Active, not recruiting - verified October 2011
 |
Shire - Database of Clinical Trials by Pharmaceutical Companies |
